FIELD: medicine; oncology.
SUBSTANCE: invention is intended for treating or slowing progression of melanoma resistant to individual antagonist B-raf. For treating or slowing progression of melanoma, resistant to B-raf antagonist in individual, effective amount of binding antagonist PD-L1, and MEK inhibitor is introduced to individual, wherein said individual previously treated with melanoma by B-raf antagonist. Said B-raf antagonist is vemurafenib, said PD-L1 agonist is an anti-PD-L1 antibody and said MEK inhibitor is GDC-0973 or a pharmaceutically acceptable salt or solvate thereof.
EFFECT: use of the invention provides higher clinical effectiveness or slower progression of melanoma resistant to vemurafenib, in an individual previously treated for melanoma with said B-raf antagonist.
19 cl, 1 tbl, 1 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO COMPONENTS OF THE SIGNAL PATH PD-1, AND TAXANES | 2014 |
|
RU2719487C2 |
| 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USE THEREOF IN TREATING DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 OF IKAROS (IKZF2) FAMILY | 2019 |
|
RU2815714C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
| ANTIBODY-DRUG CONJUGATES AND METHODS OF USING SAID CONJUGATES OF PYRROLOBENZODIAZEPINE | 2016 |
|
RU2736725C1 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| ANTI-FcRH5 ANTIBODIES | 2014 |
|
RU2687132C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | 2014 |
|
RU2825390C2 |
| 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 (IKZF2) OF THE IKAROS FAMILY | 2019 |
|
RU2797559C2 |
| HUMANIZED ANTIBODIES AND ANTIBODIES WITH MATURE AFFINITY AGAINST FcRH5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2748943C2 |
